LLS-funded researcher spotlights

The Leukemia & Lymphoma Society funds research across the continuum, from basic research through clinical trials, from bench to bedside. To date, we have invested almost $1 billion in research to advance therapies and save lives. LLS research grants have funded many of today's most promising advances, including targeted therapies and immunotherapies and some of the therapies first approved for blood cancer patients are now helping patients with other types of cancers and other serious diseases. Thanks to research and access to better treatments, survival rates for many blood cancer patients have doubled, tripled and even quadrupled since 1960.

hear from some of the world's most renowned blood cancer researchers about how LLS support helps makes it happen.



LLS funds research to advance more breakthrough therapies for blood cancer patients.

donate today


Our Investment

Gen. Leukemia
$15 M (5%)
CML
$6.5 M (2%)
Hodgkin Lymphoma
$6.3 M (2%)
Indolent NHL
$15 M (5%)
  AML
$69 M (25%)
Aggresive NHL
$16.7 M (6%)
   
CLL / SLL
$20.9 M (7%)
   
Gen. Lymphoma
$22.5 M (8%)
  ALL
$40.1 M (14%)
Myeloma
$37.1 M (13%)
  MDS / MPNs
$37.3 M (13%)


Milestones - Once unimaginable, new treatments are saving lives today



1950s
First chemo-therapy agents for lymphoma and leukemia patients, including children.
1960s
First combination chemotherapy developed for childhood leukemia.
1970s
First successful bone marrow transplants performed.
1980s
Cancer-causing oncogenes and tumor suppressor genes discovered.

1990s
Antibody-based therapies such as Rituxan.
2000s
Targeted therapies such as Gleevec.
2010s
Genomic medicine and precision medicine; adoptive immunotherapy.
2020s +
Personalized medicine cures and prevention.
last updated on Friday, February 14, 2014
btn_sharethis

E-Newsletters


Sign Up For Free

Subscribe to one of LLS's Monthly eNewsletters
Your Name

Your Email

Your Zip Code


About E-News»